Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Xenon (DE:XP0)
FRANKFURT:XP0
Xenon (XP0) Stock Price & Analysis
0 Followers
XP0 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€26.20 - €46.60
Previous Close€39
Volume0.00
Average Volume (3M)70.00
Market Cap
€2.86B
Enterprise Value€2.38B
Total Cash (Recent Filing)$526.67M
Total Debt (Recent Filing)$11.00M
Price to Earnings (P/E)N/A
Beta-0.03
Next Earnings
May 07, 2024EPS Estimate
-€0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding75,432,482
10 Day Avg. Volume0
30 Day Avg. Volume70
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)3.37
Price to Sales (P/S)310.24
Price to Cash Flow (P/CF)-22.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit252.04
Enterprise Value/Ebitda-17.77
Forecast
1Y Price Target
€55.37Price Target Upside41.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Xenon News
PremiumCompany Announcements
Xenon Pharmaceuticals Spotlights XEN1101 Progress
PremiumCompany Announcements
Xenon Pharma to Spotlight Innovations at Investor Conference
PremiumCompany Announcements
Xenon Pharmaceuticals at Needham Healthcare Conference
PremiumCompany Announcements
Xenon Pharmaceuticals Engages at Stifel CNS EventBulls Say, Bears Say
Bulls Say
Clinical Trial AdvancementsPatient enrollment in the phase 3 epilepsy program is progressing, demonstrating advancement in the company's clinical trials.
Financial StabilityThe company ended the year with a robust cash reserve, ensuring a financial runway into 2027 and showcasing strong financial planning.
Stock PerformanceAnalysts maintain a Buy rating with increased price targets, reflecting confidence in potential future revenues and the company's stock performance.
Bears Say
Clinical TrialsThe key trial, X-TOLE2, is now expected to complete enrollment later than the prior timeline.
CompetitionCompetitor's early safety data look promising with a limited immediate impact to XEN1101.
Financial PerformanceXENE reported a Q4 net loss of $44.7MM.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.22% Other Institutional Investors
99.78% Public Companies and
Individual Investors
XP0 FAQ
What was Xenon’s price range in the past 12 months?
Xenon lowest stock price was €26.20 and its highest was €46.60 in the past 12 months.
What is Xenon’s market cap?
Currently, no data Available
When is Xenon’s upcoming earnings report date?
Xenon’s upcoming earnings report date is May 07, 2024 which is in 17 days.
How were Xenon’s earnings last quarter?
Xenon released its earnings results on Feb 29, 2024. The company reported -€0.603 earnings per share for the quarter, beating the consensus estimate of -€0.715 by €0.112.
Is Xenon overvalued?
According to Wall Street analysts Xenon’s price is currently Undervalued.
Does Xenon pay dividends?
Xenon does not currently pay dividends.
What is Xenon’s EPS estimate?
Xenon’s EPS estimate is -€0.63.
How many shares outstanding does Xenon have?
Currently, no data Available
What happened to Xenon’s price movement after its last earnings report?
Xenon reported an EPS of -€0.603 in its last earnings report, beating expectations of -€0.715. Following the earnings report the stock price went down -0.905%.
Which hedge fund is a major shareholder of Xenon?
Among the largest hedge funds holding Xenon’s share is Driehaus Capital Management LLC. It holds Xenon’s shares valued at 200M.
---
Xenon Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€55.37 (41.98% Upside)
€55.37 (41.98% Upside)
Blogger Sentiment
Bullish
DE:XP0 Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $601.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
12.36%
12-Months-Change
Fundamentals
Return on Equity
-22.12%
Trailing 12-Months
Asset Growth
27.93%
Trailing 12-Months
Company Description
Xenon
Xenon Pharmaceuticals, Inc. engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P. Kastelein, and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.
---
XP0 Earnings Call
Q4 2024
0:00 / 0:00
---
XP0 Stock 12 Months Forecast
Average Price Target
€55.37
▲(41.98% Upside)
Technical Analysis
Xenon
―
Adverum Biotechnologies
―
Curis
―
Karyopharm Therapeutics
―
PTC Therapeutics
―
Best Analysts Covering XP0
1 Year
1 Year Success Rate
10/11 ratings generated profit
1 Year Average Return
+42.63%
reiterated a buy rating 4 months ago
Copying Andrew Tsai's trades and holding each position for 1 Year would result in 90.91% of your transactions generating a profit, with an average return of +42.63% per trade.
---